NEXT Oncology- Virginia

Az itteni vizsgálatok

Miről szól a helyszín 44 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák29 vizsgálat
• Vastagbélrák17 vizsgálat
• Hasnyálmirigyrák12 vizsgálat
• Petefészekrák9 vizsgálat
• Gyomor- és nyelőcsőrák8 vizsgálat
• Prosztatarák7 vizsgálat
• Fej-nyaki daganatok6 vizsgálat
• Méhtestrák6 vizsgálat
• Hólyagrák5 vizsgálat
• Melanóma5 vizsgálat
• Mezotelióma4 vizsgálat
• Máj- és epeúti rák3 vizsgálat
• és még 11

Fázis

• 1. fázis25 vizsgálat
• 1/2. fázis18 vizsgálat
• 2. fázis1 vizsgálat

Állapot

• Toboroz27 vizsgálat
• Fut, nem toboroz7 vizsgálat
• Leállították5 vizsgálat
• Lezárult4 vizsgálat
• Visszavonták1 vizsgálat

Fő szponzor

• Revolution Medicines, Inc.5 vizsgálat
• Alentis Therapeutics AG2 vizsgálat
• Astellas Pharma Inc2 vizsgálat
• IDEAYA Biosciences2 vizsgálat
• Tango Therapeutics, Inc.2 vizsgálat
• és még 31

Futó vizsgálatok

• Toboroz

  Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

  NCT07807345· 1. fázis· Sutro Biopharma, Inc.· Forrás

  Contact: Maybelle De La Rosa

• Toboroz

  Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

  NCT07723703· 1. fázis· Amphista Therapeutics Ltd· Forrás

  Contact: Amphista Medical Monitor

• Toboroz

  A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

  NCT07779798· 1. fázis· Crossbow Therapeutics, Inc.· Forrás

  Contact: Maybelle De La Rosa

• Toboroz

  A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

  NCT07542704· 1. fázis· Kumquat Biosciences Inc.· Forrás

  Contact: Alexander Spira MD

• Toboroz

  AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

  NCT07454642· 1. fázis· Avacta Life Sciences Ltd· Forrás

  Contact: Maybelle De La Rosa

• Toboroz

  A 2-part Phase 1/2 Open-label Trial on ODM-212

  NCT07563738· 1/2. fázis· Orion Corporation, Orion Pharma· Forrás

  Contact: Alexander Spira, MD

• Toboroz

  A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  NCT07277413· 1. fázis· IDEAYA Biosciences· Forrás

  Contact: Maybelle De La Rosa

• Toboroz

  Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

  NCT07424547· 1. fázis· Conjupro Biotherapeutics, Inc.· Forrás

  Contact: Dr Salkeni, Principal Investigator

• Toboroz

  A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  NCT07361562· 1. fázis· Cogent Biosciences, Inc.· Forrás

  Contact: Cogent Biosciences, Inc

• Toboroz

  A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

  NCT07174583· 1/2. fázis· IDEAYA Biosciences· Forrás

  Contact: IDEAYA Clinical Trials

• Toboroz

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· 1/2. fázis· Alentis Therapeutics AG· Forrás

  Contact: Principal Investigator

• Toboroz

  A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  NCT07094204· 1. fázis· Astellas Pharma Inc· Forrás

  Contact: Astellas Pharma Global Development, Inc.

• Toboroz

  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  NCT07080242· 1. fázis· SystImmune Inc.· Forrás

  Contact: Carrie Friedman, RN, BSN, OCN

• Toboroz

  A Study of PHST001 in Advanced Solid Tumors

  NCT06840886· 1. fázis· Pheast Therapeutics· Forrás

  Contact: Carrie Friedman

• Toboroz

  A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

  NCT06785636· 1/2. fázis· Pathos AI, Inc.· Forrás

  Contact: Blake Patterson

• Fut, nem toboroz

  Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

  NCT06781983· 1. fázis· Innate Pharma· Forrás

• Toboroz

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  NCT06747585· 1/2. fázis· Alentis Therapeutics AG· Forrás

• Toboroz

  A Study of DM005 in Patients With Advanced Solid Tumors

  NCT06515990· 1/2. fázis· Doma Biopharmaceutical（Suzhou）Co., Ltd.· Forrás

  Contact: ALEXANDER SPIRA

• Toboroz

  A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  NCT06326411· 1. fázis· Nested Therapeutics, Inc· Forrás

  Contact: Blake Patterson

• Fut, nem toboroz

  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

  NCT06239467· 1. fázis· OnKure, Inc.· Forrás

• Toboroz

  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  NCT06162221· 1/2. fázis· Revolution Medicines, Inc.· Forrás

  Contact: Blake Patterson

• Toboroz

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· 1/2. fázis· Revolution Medicines, Inc.· Forrás

  Contact: Revolution Medicines, Inc.

• Fut, nem toboroz

  A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

  NCT05873686· 1. fázis· Nuvectis Pharma, Inc.· Forrás

• Toboroz

  IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

  NCT06119685· 1/2. fázis· Indapta Therapeutics, INC.· Forrás

  Contact: Blake Patterson

• Toboroz

  Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06040541· 1. fázis· Revolution Medicines, Inc.· Forrás

  Contact: Revolution Medicines, Inc.

• Fut, nem toboroz

  Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

  NCT05887492· 1/2. fázis· Tango Therapeutics, Inc.· Forrás

• Toboroz

  Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

  NCT05732831· 1/2. fázis· Tango Therapeutics, Inc.· Forrás

  Contact: Alexander Spira, MD, PhD (principal investigator)

• Toboroz

  A Study of ASP1002 in Adults for Treatment of Solid Tumors

  NCT05719558· 1. fázis· Astellas Pharma Global Development, Inc.· Forrás

  Contact: Astellas Pharma Global Development, Inc.

• Fut, nem toboroz

  A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

  NCT05653752· 1. fázis· MediLink Therapeutics (Suzhou) Co., Ltd.· Forrás

• Fut, nem toboroz

  Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

  NCT05462717· 1. fázis· Revolution Medicines, Inc.· Forrás

• Toboroz

  A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  NCT05377996· 1/2. fázis· Day One Biopharmaceuticals, Inc.· Forrás

  Contact: Alex Spira, MD, PhD

• Toboroz

  Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  NCT05379985· 1/2. fázis· Revolution Medicines, Inc.· Forrás

  Contact: Revolution Medicines, Inc.

• Fut, nem toboroz

  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

  NCT04485013· 1. fázis· Tizona Therapeutics, Inc· Forrás

• Toboroz

  Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

  NCT03715933· 1. fázis· Inhibrx Biosciences, Inc· Forrás

  Contact: Anthony Young

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák17 toboroz
• Vastagbélrák10 toboroz
• Hasnyálmirigyrák7 toboroz
• Gyomor- és nyelőcsőrák4 toboroz
• Méhtestrák4 toboroz
• Petefészekrák4 toboroz
• Fej-nyaki daganatok3 toboroz
• Hólyagrák3 toboroz
• Máj- és epeúti rák3 toboroz
• Mezotelióma3 toboroz
• Prosztatarák3 toboroz
• Szarkóma3 toboroz
• Melanóma2 toboroz
• Neuroendokrin daganatok2 toboroz
• Akut mieloid leukémia (AML)1 toboroz
• Glioblasztóma1 toboroz
• Gyermekkori daganatok1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mielóma multiplex1 toboroz
• Tripla negatív emlőrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás

• Toboroz

  A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

  NCT06616766· 1/2. fázis· Yuhan Corporation· Forrás

  Contact: Yuhan Corporation Clinical Operation Team 1

• Leállították

  Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

  NCT06287463· 1. fázis· Deciphera Pharmaceuticals, LLC· Forrás

• Leállították

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· 1. fázis· Astellas Pharma Inc· Forrás

• Lezárult

  A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

  NCT06403436· 1. fázis· TOLREMO therapeutics AG· Forrás

• Leállították

  A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

  NCT05716295· 1/2. fázis· Medikine, Inc.· Forrás

• Lezárult

  Study Of ATRN-119 In Patients With Advanced Solid Tumors

  NCT04905914· 1/2. fázis· Aprea Therapeutics· Forrás

• Visszavonták

  A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

  NCT05279859· 1/2. fázis· Erasca, Inc.· Forrás

• Leállították

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· 1/2. fázis· Merus B.V.· Forrás

• Lezárult

  A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

  NCT03819387· 1. fázis· Nitto BioPharma, Inc.· Forrás